As of close of business last night, Privia Health Group Inc’s stock clocked out at $22.33, up 3.86% from its previous closing price of $21.50. In other words, the price has increased by $+0.83 from its previous closing price. On the day, 808103 shares were traded.
Ratios:
To gain a deeper understanding of PRVA’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 6.80 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 32.82. For the most recent quarter (mrq), Quick Ratio is recorded 1.81 and its Current Ratio is at 1.81. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Barclays on March 06, 2024, initiated with a Equal Weight rating and assigned the stock a target price of $22.
BofA Securities Downgraded its Buy to Neutral on February 22, 2024, while the target price for the stock was maintained at $21.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jan 25 ’24 when Sullivan William M sold 12,000 shares for $23.13 per share. The transaction valued at 277,560 led to the insider holds 5,452,533 shares of the business.
Sullivan William M sold 9,951 shares of PRVA for $229,172 on Jan 24 ’24. The Director now owns 5,464,533 shares after completing the transaction at $23.03 per share. On Dec 28 ’23, another insider, Sullivan William M, who serves as the Director of the company, sold 12,000 shares for $23.97 each. As a result, the insider received 287,640 and left with 5,474,484 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PRVA now has a Market Capitalization of 2.65B and an Enterprise Value of 2.27B. As of this moment, Privia’s Price-to-Earnings (P/E) ratio for their current fiscal year is 120.57, and their Forward P/E ratio for the next fiscal year is 66.96. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.60 while its Price-to-Book (P/B) ratio in mrq is 4.70. Its current Enterprise Value per Revenue stands at 1.37 whereas that against EBITDA is 83.38.
Stock Price History:
Over the past 52 weeks, PRVA has reached a high of $30.15, while it has fallen to a 52-week low of $19.17. The 50-Day Moving Average of the stock is 21.56, while the 200-Day Moving Average is calculated to be 23.59.
Shares Statistics:
It appears that PRVA traded 920.69K shares on average per day over the past three months and 1.39M shares per day over the past ten days. A total of 118.22M shares are outstanding, with a floating share count of 102.06M. Insiders hold about 13.92% of the company’s shares, while institutions hold 96.00% stake in the company. Shares short for PRVA as of Feb 15, 2024 were 6.59M with a Short Ratio of 7.16, compared to 6.26M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 5.58% and a Short% of Float of 10.33%.
Earnings Estimates
As of right now, 12 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of $0.05 for the current quarter, with a high estimate of $0.07 and a low estimate of $0.03, while EPS last year was $0.06. The consensus estimate for the next quarter is $0.06, with high estimates of $0.08 and low estimates of $0.04.
Analysts are recommending an EPS of between $0.33 and $0.17 for the fiscal current year, implying an average EPS of $0.24. EPS for the following year is $0.33, with 12 analysts recommending between $0.4 and $0.23.
Revenue Estimates
In the current quarter, 8 analysts expect revenue to total $682.4M. It ranges from a high estimate of $700M to a low estimate of $652.3M. As of the current estimate, Privia Health Group Inc’s year-ago sales were $658.9M, an estimated increase of 3.60% from the year-ago figure.
Based on 8 analysts’ estimates, the company’s revenue will be $3.26B in the next fiscal year. The high estimate is $3.51B and the low estimate is $3.15B. The average revenue growth estimate for next year is up 14.80% from the average revenue estimate for this year.
